Showing results (251-260 of 279) with videos related to

Sort By:
Pageof 28
The Lancet. Oncology|May 17, 2014
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trialEugene D Kwon, Charles G Drake, Howard I Scher, et al.
Scientific Reports|July 2, 2021
Relevance of circulating hybrid cells as a non-invasive biomarker for myriad solid tumorsMatthew S Dietz, Thomas L Sutton, Brett S Walker, et al.
JCO Oncology Practice|December 19, 2024
Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is NowNeal Shore, Sarah M Nielsen, Edward D Esplin, et al.
European Urology|April 1, 2019
Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate CancerWilliam S Chen, Rahul Aggarwal, Li Zhang, et al.
The New England Journal of Medicine|June 3, 2014
Enzalutamide in metastatic prostate cancer before chemotherapyTomasz M Beer, Andrew J Armstrong, Dana E Rathkopf, et al.
Cancer Research|June 8, 2023
The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate CancerArian Lundberg, Meng Zhang, Rahul Aggarwal, et al.
JCO Oncology Practice|September 28, 2020
Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTCBrittany M Szymaniak, Lauren A Facchini, Veda N Giri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 10, 2018
Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective StudyRahul Aggarwal, Jiaoti Huang, Joshi J Alumkal, et al.
European Urology Open Science|December 22, 2021
Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical ProstatectomyKaren A Autio, Emmanuel S Antonarakis, Tina M Mayer, et al.
NPJ Precision Oncology|July 7, 2025
Transcriptional profiling clarifies a program of enzalutamide extreme non-response in lethal prostate cancerAnbarasu Kumaraswamy, Ya-Mei Hu, Joel A Yates, et al.
Pageof 28